TheNewswire - December 21 st, 2020  -  Solarvest BioEnergy Inc. ("Solarvest", or the "Company") (TSXV:SVS), Solarvest, through it's 100% wholly owned subsidiary Eversea TM is pleased to announce plans to launch its Organic Omega-3 nutritional Gummy Fruit Drops for children after the year-end holiday break.  The fruit drop has been produced and passed quality control under high standards from our German contract manufacturer.  The final phase is to confirm the quality of the product after the logistics of shipping and packaging which is underway.  The Company's first of its kind nutritional gummy product will be an exceptional competitor in the large and rapidly growing gummy supplement market.  The organic gummy contains Solarvest's proprietary, certified organic, Omega-3 DHA powder, a sustainable, plant based powder designed for organic, vegetarian and vegan consumers.

The Company is actively working to add unique products to satisfy the demand for premium organic, Omega-3 and plant-based health products.  This first labelled product will soon commence sales in the USA and be available from the company's E-commerce web site ( ) and through Amazon. Eversea will be capable of providing organic oriented retailers with house branded products based on our patented ingredient (differentiation), so that they may take benefit from the extensive market demand for the product's unique characteristics, particularly for organic and vegan diets.

The company also announces the completion of its USA infrastructure and logistics system for order processing. Our west coast distribution point is located close to the primary and most important market for organic and plant based supplements/foods.  In addition this strategic location is close to organic food processors, sustainable oriented consumers and the organic baby food market.  The facility is capable of nation-wide distribution.

The Eversea Omega-3 powder is USDA and EU Organic Certified and produced from the Company's sustainable, proprietary process.  Gerri Greenham, CEO, notes that, "Our omega 3's are sustainable because they are expressed in algae and grown in controlled facilities which eliminates the need to harvest marine species.  Our technology produces an organically certified, highly bioavailable long-chain Omega-3 that cannot be produced by common plant species such as flaxseed or hemp which only contain ALA Omega-3.  Our customers are buying a product to improve health so they want an organic product which has a clean label of ingredients."  The Company also intends to sell the powder supplement to organic food processors and marketers, such as baby food suppliers, to facilitate the development of enhanced patent-protected products. The Company also intends to pursue other premium animal health applications such as high Omega-3 eggs, pet supplements and food. "

Eversea has also initiated a second product run with its German-based organically certified manufacturer to supplement inventory levels domestically and initiate international sales. Recognizing that Eversea's organically certified product holds a competitive advantage with several differentiating factors focused on sustainability, environmental conservation, bioavailability and purity, the Company will be able to deliver alternatives for the adult, seniors, infant formula and maternity markets to complement its adolescent offering.

Market Overview

"The EPA and DHA omega-3 finished product market size reached US$44.2 billion in 2019. as stated in the  2020 Global EPA &DHA Finished Goods Report.  Market dynamics and new product development are driving increased growth in certain product categories and across several regions of the world, leading the global EPA and DHA consumer product market to a projected annual growth rate of 6.1% for 2020–2021".

"The global gummy vitamins market size is estimated to be valued at USD 5.9 billion in 2020 and projected to reach USD 10.6 billion by 2025, recording a CAGR of 12.5%, in terms of value" as stated by Reportlinker in Oct 27, 2020 PRNewswirepress release.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2020 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Gummy Project Announces Official Launch of E-Commerce Sales Channel

The Gummy Project Announces Official Launch of E-Commerce Sales Channel

  • The Gummy Project'S Watermelon Sharks and Peachy Bees are now available for pre-sale purchase at
  • Shipping and fulfilment of online orders will commence on July 11, 2022

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce the official launch of its new e-commerce site at

"The launch of our e-commerce site is a major milestone, making our product available across Canada for the first time," said Anthony Gindin, Chief Marketing Officer at GUMY. "This really marks our official launch into the Canadian market with e-commerce being a major component in our overall sales channel strategy. The site provides a vehicle for continued growth as well as a platform to share our story and fulfil our mandate to support endangered keystone species."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2022. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular.

Resolutions proposed and approved at the AGM were:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

The Gummy Project Announces Another Milestone with Entry into Canadian Retail Market

  • The Gummy Project'S Watermelon Sharks and Peachy Bees to be sold at Vancouver based Stong's Markets
  • Stong's are Vancouver owned full-service grocery stores that have operated in Vancouver since 1931

The Gummy Project (CSE: GUMY) (FSE: 0OS2) (OTCQB: POTVF) ("GUMY" or the "Company") is pleased to announce that as of June 29, 2022 it has partnered with Stong's to launch its Watermelon Sharks and Peachy Bees into the Canadian retail market.

"This partnership represents another great step in our ongoing sales strategy and we're extremely proud to partner with Stong's, an iconic grocery store in Vancouver," said Charlie Lamb, President and CEO of GUMY. "Following our recent partnership announcements with Flair Airlines and Bard on the Beach, the upcoming launch of our ecommerce site on June 30 2022, and our distribution partnership with Dean's Dairy and Specialty Foods, consumers will soon be able to purchase our products at locations across Canada."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Health Canada Approves OPDIVO® as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma at High Risk of Recurrence after Undergoing Radical Resection of UC

First adjuvant Immunotherapy for patients at high risk of disease recurrence

Today, Bristol Myers Squibb Canada (BMS) announced Health Canada has issued a Notice of Compliance with Conditions (NOCc) for OPDIVO ® , as a monotherapy for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. i OPDIVO ® is the first immuno-oncology treatment to bring benefit in the adjuvant setting of UC and represents a potential new standard of care for patients at high risk of disease recurrence. ii Unlike traditional cancer therapies that target the tumour directly, immuno-oncology activates the body's own immune system to help recognize and attack cancer cells. iii

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Kite's CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

Pivotal ZUMA-5 Study Demonstrates Overall Response Rate of 91% and a Complete Response rate of 77% in Patients Who Received Yescarta After Three or More Lines of Therapy –

Kite's Third Approved Cell Therapy Indication in Europe

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

NDA Resubmission Addresses Issues Related to Vial Compatibility –

If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News